50 Questions Families Ask About Stem Cell Therapy for Autism

About Stem Cells

1. What are stem cells?

Stem cells are undifferentiated cells capable of self-renewal and differentiation into specialised cell types. In medical therapy, they are also valued for their ability to secrete bioactive factors that influence surrounding tissue.

2. What type of stem cells are used for autism?

Most autologous ASD protocols use mesenchymal stem cells (MSCs), derived from bone marrow or adipose tissue. MSCs have well-characterised anti-inflammatory and neurotrophic properties.

3. Are embryonic stem cells used?

No. Autologous protocols use the patient's own adult stem cells. Embryonic stem cells are not used in these protocols.

4. What is the difference between autologous and allogeneic therapy?

Autologous: cells from the patient's own body. Allogeneic: cells from a donor. Autologous therapy eliminates immune rejection risk and is the standard for paediatric ASD protocols.

5. Do stem cells stay in the brain?

Most cells administered intravenously do not cross the blood-brain barrier. Their effect is primarily paracrine — secreting anti-inflammatory and neurotrophic factors that influence the brain's environment systemically.

About Autism and This Treatment

6. Why is stem cell therapy being studied for autism?

Because autism frequently involves neuroinflammation and immune dysregulation — both mechanisms that mesenchymal stem cells are known to influence.

7. Is this a cure for autism?

No. There is no cure for autism, and no legitimate programme claims to offer one.

8. What improvements are reported?

Most commonly: improved social communication, increased spontaneous language, better attention and focus, reduced anxiety, improved sleep, and reduced sensory sensitivities. Not all of these occur in every child.

9. How long do improvements last?

Duration of effects varies. Many families report sustained gains at 12-month and 24-month follow-up. Some children benefit from repeat sessions.

10. Is autism "caused" by inflammation?

Neuroinflammation is a documented feature in many — not all — autistic individuals. It is one contributing factor among several, not the sole cause.

About Eligibility

11. What age range is appropriate?

Typically 2–16 years, with younger children often showing stronger response. Individual cases outside this range are assessed.

12. Are nonverbal children candidates?

Yes. Nonverbal status does not exclude a child; it may indicate the inflammatory/immune profile that responds best to this therapy.

13. Does my child need a formal diagnosis?

Yes. A formal ASD diagnosis from a licensed clinician is required.

14. Are children with epilepsy eligible?

Well-controlled, stable epilepsy is evaluated case by case. Uncontrolled seizures are a contraindication.

15. Are children on medication eligible?

Medication is not an automatic exclusion. The evaluation reviews current medications and assesses any interaction considerations.

About the Evaluation

16. What is the pre-evaluation?

QEEG brain mapping, biomarker blood panel, clinical history review, and a detailed family consultation.

17. Can we do any evaluation remotely?

Biomarker panels can often be arranged through local laboratories with remote result review. QEEG typically requires in-person assessment.

18. How long does evaluation take?

Typically 4–6 weeks from initial consultation to treatment decision.

19. What if our child is not a suitable candidate?

The evaluation findings remain valuable regardless. The team will explain the findings and discuss what they indicate for your child's care.

20. Is the initial consultation free?

Yes. The initial consultation with our coordinator is free.

About Safety

21. Is this safe?

Autologous stem cell therapy has a well-characterised safety profile in published paediatric trials. Serious adverse events are uncommon.

22. What side effects might occur?

Most commonly: temporary fatigue (1–3 days), minor discomfort at the collection site, occasional low-grade temperature that resolves quickly.

23. Is general anaesthesia safe for young autistic children?

General anaesthesia is routinely used in paediatric medicine. Pre-anaesthesia assessment is completed before the procedure.

24. Could my child get worse after treatment?

Temporary regression is occasionally reported in the early weeks — often followed by subsequent progress. Sustained regression is not a documented outcome in published trials.

25. What is GMP certification and why does it matter?

GMP (Good Manufacturing Practice) certification means the laboratory meets international quality, sterility and documentation standards for cell processing. It is non-negotiable.

About the Procedure

26. How are cells collected?

Via bone marrow aspiration from the posterior pelvic bone under general anaesthesia, or from adipose tissue via minor lipoaspiration.

27. How long is the procedure?

Collection takes 20–40 minutes. Total procedure time including anaesthesia is 1–2 hours.

28. How are cells administered?

Most commonly intravenously. Some protocols include intrathecal (into the spinal fluid) administration for more direct CNS access.

29. How long does my child need to be in hospital?

Most children leave the clinical facility the same day or after one overnight stay.

30. How many sessions are needed?

This varies by child profile and response. Many children complete one session with meaningful benefit; some benefit from a second session at 12–18 months.

About Results

31. When will we see results?

Changes typically begin to emerge between 4–12 weeks, with more substantial development at 3–6 months.

32. Is improvement guaranteed?

No. Response varies by individual. An ethical programme does not guarantee outcomes.

33. What percentage of children improve?

Published trial data suggests meaningful improvement in a majority of appropriate candidates, but variability is real. Individual biomarker and QEEG profiles are the best predictors.

34. How is progress tracked?

QEEG follow-up at 3, 6 and 12 months provides objective neurological data. Standardised behavioural assessments and family documentation supplement this.

35. What if we don't see results?

The 3-month QEEG follow-up is the appropriate time to assess response. If no changes are observed at this point, the clinical team will discuss the findings honestly.

About Supportive Therapies

36. Should we continue speech therapy during treatment?

Yes. Stem cell therapy creates a more receptive neurological environment; existing therapies provide the structured input to capitalise on it.

37. Should we change our child's therapy programme after treatment?

Generally, maintain existing therapies during the initial 3-month period. Adjust based on 3-month follow-up findings.

38. Is diet important?

A nutritious, whole-food diet and attention to gut health supports the overall biological environment. The clinical team will provide specific guidance during the consultation.

39. Can we use complementary interventions alongside this?

Some complementary approaches are supportive; others may interact. Discuss any planned additions with the clinical team before proceeding.

40. What about neurofeedback?

QEEG-guided neurofeedback can be an appropriate complementary intervention. Discuss timing and integration with the clinical team.

About Logistics

41. Do we need to travel to Turkey?

For the procedure itself, yes. Pre-evaluation steps can often be partially completed remotely.

42. How long should we plan to stay?

Most families plan for 5–7 days, including arrival, pre-procedure preparation, the procedure, and initial recovery.

43. Is English spoken at the clinic?

Yes. Our international coordinator team communicates in English. Confirm this with any clinic you evaluate.

44. What does follow-up look like after we return home?

Remote consultation via video call, with QEEG follow-up arranged locally if available. Blood panels for biomarker follow-up can be arranged through local laboratories.

45. How do we prepare our autistic child for travel?

Visual schedules, direct flights where possible, familiar comfort items and foods, and advance planning with the airline. Our coordinator provides a pre-travel preparation guide.

About Cost

46. What does the full programme cost?

Costs vary based on the specific protocol. A detailed cost breakdown is provided following the initial evaluation, before any commitment is required.

47. Is this covered by insurance?

In most countries, autologous stem cell therapy for autism is not covered by standard health insurance. Some families have explored medical credit facilities or fundraising approaches.

48. Are there hidden costs?

The full programme cost includes evaluation, cell collection, processing, and administration. Travel, accommodation, and local follow-up costs are separate and are outlined transparently.

49. Do we pay anything before the evaluation?

The initial consultation is free. Evaluation costs are discussed and confirmed before the evaluation proceeds.

50. Is there a payment plan?

Payment structure options are discussed during the consultation process. No family should be pressured to commit financially before receiving full evaluation findings.